LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment
LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment
To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (Herceptin®) treatment
Inclusion criteria:
Exclusion criteria:
Capital Federal, C1280AEB, Argentina
Ciudad Autonoma de Bs As, C1050AAK, Argentina
Minsk Region, 223040, Belarus
Haerbin, 150081, China
Maharagama, India
Dubliin 9, Ireland
Kanagawa, Isehara, 259-1193, Japan
Osaka, Osaka, 537-8511, Japan
Tokyo, Chuo-ku, 104-0045, Japan
Lebanon, Lebanon
Rondebosch, Cape Town, 7700, South Africa
Las Palmas de Gran Canaria, 35016, Spain
Maharashtra, 422002, Sri Lanka
Taoyuan County, 333, Taiwan
Woolwich, London, SE18 4QH, United Kingdom